Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 976 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endothelial Clear all

Conditions: Atherosclerosis, Endothelial Dysfunction
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 20 Years to 90 Years
Enrollment: 223 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Coronary Artery Disease
Interventions: Egg supplementation, Egg substitute, Control diet; Dietary Supplement
Lead sponsor: Griffin Hospital; Other
Eligibility: 35 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Tumors, Neoplasm Metastasis
Interventions: PTK787/ZK 222584 (vatalanib); Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prehypertension, Hypertension
Interventions: Nebivolol, Metoprolol, Placebo, Bradykinin, Saline, Vitamin C; Drug · Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 45 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer, Liposarcoma
Interventions: Ionizing radiation (IR) therapy, Ionizing radiation (IR); Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Metabolic Syndrome
Interventions: Etanercept, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Macular Edema
Interventions: 2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 90
States / cities: Tucson, Arizona • Beverly Hills, California • Loma Linda, California + 72 more

Conditions: Cardiovascular Diseases, Vascular Dilation
Interventions: Ifetroban Sodium, Placebo; Drug
Lead sponsor: Jeffrey Rade; Other
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Peritoneal Cancer
Interventions: Bevacizumab, Oxaliplatin, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fuchs Endothelial Corneal Dystrophy
Interventions: Ripasudil, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 26
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more

Conditions: Diabetes Mellitus, Metabolic Syndrome X, Hypercholesterolemia
Interventions: Atorvastatin, Pravastatin; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Kidney Disease
Interventions: Research diet; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV, COPD, Emphysema, Smoking
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoking, Endothelial Dysfunction
Interventions: Electronic hookah vaping with nicotine, Electronic hookah vaping without nicotine; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 39 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more

Conditions: Corneal Transplantation
Interventions: EndoSaver™ Corneal Endothelium Delivery Instrument; Device
Lead sponsor: Ocular Systems, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: GVHD,Acute
Interventions: blood sample; Diagnostic Test
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Polycystic Ovary Syndrome (PCOS)
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 14 Years to 40 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Renal Function, Endothelial Function, Blood Pressure, Overweight, Obesity
Interventions: Vitamin D ergocalciferol, Probenecid, Allopurinol, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions: AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose, AR-13503 63.6 Dose; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Gilbert, Arizona • Beverly Hills, California • Walnut Creek, California + 3 more

Conditions: Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
Interventions: BNT323, BNT327; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 29
States / cities: Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 19 more

Conditions: Diabetes Mellitus, Type 1, Endothelial Dysfunction
Interventions: Dulaglutide, Placebo; Drug
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 40 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Older Adults
Interventions: low sodium/low potassium diet, high sodium/low potassium diet, high sodium/high potassium diet; Other
Lead sponsor: Florida State University; Other
Eligibility: 55 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tallahassee, Florida

Search by objective public record fields.

Predictive Medicine Research

Effects of Egg Ingestion on Endothelial Function in Adults With Coronary Artery Disease

Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer

Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Study of TNF-Antagonism in the Metabolic Syndrome (II)

Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema

Thromboxane Receptor Antagonist to Improve Endothelial Function

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease

Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD

HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium

Electronic Hookah and Endothelial Cell Function

Anti-VEGF Treatment for Prevention of PDR/DME

Corneal Endothelium Delivery Instrument

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

Blood Vessel Function in Adolescents and Women With Polycystic Ovary Syndrome

Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Interactive Effects of Sodium and Potassium on Vascular Health in Older Adults